Law360, New York (August 24, 2011, 2:18 PM EDT) -- UCB Pharma SA and Par Pharmaceutical Inc. on Monday settled a suit Par had filed in Pennsylvania seeking a court declaration that two UCB patents were invalid and not infringed by Par's proposed generic version of the epilepsy drug Keppra.
Solely for the purpose of enforcing the parties' agreement, Par conceded that the two patents-in-suit were valid and enforceable and would be infringed by the marketing of the Par proposed generic levetiracetam extended-release tablets, according to a stipulation and order signed by U.S. District Judge Mitchell S. Goldberg.
Pursuant to a settlement and license agreement, Par and UCB stipulated that "this...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!